Oral estramustine and oral etoposide for hormone-refractory prostate cancer
- 30 November 1997
- Vol. 50 (5), 754-758
- https://doi.org/10.1016/s0090-4295(97)00323-3
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Estramustine Phosphate Versus Placebo as Second Line Treatment After Orchiectomy in Patients With Metastatic Prostate Cancer: Daproca Study 9002Journal of Urology, 1997
- Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.Journal of Clinical Oncology, 1994
- Oral etoposide in the treatment of hormone-refractory prostate cancerCancer, 1994
- Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.Journal of Clinical Oncology, 1994
- Mitomycin C Versus Estramustine in the Treatment of Hormone Resistant Metastatic Prostate Cancer: Thefinal Analysis of the European Organization Forresearch and Treatment of Cancer, Genitourinarygroup Prospective Randomized Phase III Study (30865)Journal of Urology, 1993
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Inhibition of Prostate Cancer Growth by Estramustineand Etoposide: Evidence For Interaction at the Nuclear MatrixJournal of Urology, 1993
- Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1992
- Estramustine and Vinblastine: Use of Prostate Specific Antigen as a Clinical Trial End Point for Hormone Refractory Prostatic CancerJournal of Urology, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958